The AIM-HN and SEQ-HN Study: A 2 Cohort Non-comparative Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN)
Brief description of study
The purpose of this research study is to see how effective the study drug is to treat your tumor. Other reasons for conducting the study are: • To determine for how long the study drug may reduce the size or slow down the growth of your tumor. • To determine the side effects of the study drug. • To study your tumor and determine why it responds or not to treatment with this study drug.
Clinical Study Identifier: s18-00146
ClinicalTrials.gov Identifier: NCT03719690
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
